Market Segmentation:
- By Treatment Type
- Antiparasitic Medication
- Symptomatic and Supportive Treatment
- Vaccines
- Others (stem cell therapy, gene therapy)
- By Diagnostic Test
- Microscopic Examination
- Molecular Tests (PCR)
- Immunodiagnostics (ELISA)
- Others (imaging, cultures)
- By End-User
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
- Others (blood banks, NGOs)
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current Chagas disease treatment market size is around US$ 300 million.
High prevalence in Latin American countries, Advances in diagnostics and treatment, Implementation of screening and control programs, Rising awareness and access to healthcare
Low awareness in remote endemic regions, High cost of treatment, Complex regulatory pathways, Lack of funding and resources
The antiparasitic drugs segment leads the Chagas disease market.
Sanofi, Bayer, Abbott, Chemo, Merck, Eisai, Celgene, Insud Pharma, Exeltis, Immune Therapeutics
CAGR of 6.5%; Market size of US$ 496.5 million in 2031
High prevalence in Latin America, Growing R&D into new treatments, Advances in diagnostics and screening, Rising awareness and control programs, Increasing healthcare access and expenditure